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Chronic kidney disease (CKD) is a common clinical condition with significant adverse consequences for the patient and it is recognized as a significant 
public health problem. The role of laboratory medicine in diagnosis and management of CKD is of great importance: the diagnosis and staging are 
based on estimation of glomerular filtration rate (eGFR) and assessment of albuminuria (or proteinuria). Therefore, the joint working group of the 
Croatian society of medical biochemistry and laboratory medicine and Croatian chamber of medical biochemists for laboratory diagnostics in CKD 
issued this national recommendation regarding laboratory diagnostics of CKD.
Key factors for laboratories implementing the national guidelines for the diagnosis and management of CKD are:
1. Ensure good communication between laboratory professionals and clinicians, such as nephrologists or specialists in general/family medicine,
2. Ensure all patients are provided with the same availability of laboratory diagnostics,
3. Ensure creatinine assays are traceable to isotope dilution mass spectrometry (IDMS) method and have minimal bias and acceptable imprecision,
4. Select the appropriate GFR estimating formula. Recommended equation is the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD – 
EPI) equation,
5. In reporting the key laboratory tests (creatinine, eGFR, urine albumin-to-creatinine ratio, urine protein-to-creatinine ratio) use the appropriate 
reporting units, 
6. Provide adequate information on limitations of creatinine measurement.
The manuscript has been organized to identify critical points in laboratory tests used in basic laboratory diagnostics of CKD and is based on the 
Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 
Key words: chronic kidney disease (CKD); recommendations, estimated glomerular filtration rate (eGFR); albuminuria; proteinuria
Received: March 13, 2015 Accepted: December 08, 2016
The role of laboratory testing in detection and classification of chronic kidney 
disease: national recommendations
Vanja Radišić Biljak*1, Lorena Honović2, Jasminka Matica3, Branka Krešić4, Sanela Šimić Vojak5
On behalf of the joint working group of the Croatian society of medical biochemistry and laboratory medicine and Croatian chamber 
of medical biochemists for laboratory diagnostics in chronic kidney disease
1Department of medical biochemistry and laboratory medicine, Merkur University Hospital, Zagreb, Croatia
2Department of medical biochemistry and laboratory medicine, General Hospital Pula, Pula, Croatia
3Medical-biochemistry laboratory, Primary care center of the Primorje-Gorski Kotar County, Rijeka, Croatia
4Department of medical laboratory diagnostics, University Hospital Centre Split, Split, Croatia
5Department of laboratory diagnostics, General County Hospital Požega, Požega, Croatia
*Corresponding author: vanja.radisic@gmail.com
Introduction
Chronic kidney disease (CKD) is a common clinical 
condition with significant adverse consequences 
for the patient. It is recognized as a significant 
public health problem throughout the world (1). 
Many publications report the prevalence of CKD in 
the general population, however there are consid-
erable variation in methods for sampling general 
population and assessment of kidney function 
Biochemia Medica 2017;27(1):153–76  http://doi.org/10.11613/BM.2017.019 
154
Radišić Biljak V. et al. CSMBLM and CCMB recommendations for CKD testing 
across studies (2). This makes comparison of stud-
ies rather difficult, however worldwide prevalence 
of adult CKD is about 10%, reaching up to 50% in 
high-risk population (3). Late recognition and di-
agnosis of disease inevitably leads to kidney fail-
ure (1). In this case the only possible therapeutic 
measure is dialysis or transplantation in health 
care systems where such treatment is available. In 
those countries, where access to dialysis and trans-
plantation service may be limited or unavailable, 
the final consequence of progressive CKD is death. 
Earlier stages of kidney disease are often asympto-
matic and are usually discovered through various 
comorbid conditions, and may be reversible. It is 
of great importance, due to right time treatment 
and improving the quality of life of patients with 
CKD, but also because of the significant financial 
savings, to identify disease at an early stage where 
it is still possible to stop or slow down progression 
(1). Although, to this point, there had not been of-
ficial complete epidemiological studies conducted 
regarding CKD (prof. Mirjana Sabljar Matovinović, 
personal communication), the availability of treat-
ment in Croatia includes both, dialysis and trans-
plantation (4).
In 2002 the US Kidney Disease Outcomes Quality 
Initiative (KDOQI) group published the Clinical 
Practice Guidelines for Chronic Kidney Disease: 
Evaluation, Classification, and Stratification. Update 
of these guidelines and recommendations: Clinical 
Practice Guideline for the Evaluation and Manage-
ment of Chronic Kidney Disease was released in 
2012 under the direction of Kidney Disease: Improv-
ing Global Outcomes (KDIGO). Our national recom-
mendations for laboratory diagnosis of chronic kid-
ney disease are mainly based on the 2012 KDIGO 
guidelines, and written permission was obtained 
to reproduce the parts of the KDIGO guidelines. 
KDIGO guidelines are the product of cooperation 
of a large number of international experts who 
created recommendations, among other things, to 
be used for good laboratory practice in the diag-
nosis and management of CKD.
Chronic kidney disease is defined as an abnormali-
ty of kidney structure or function with implica-
tions on the health of an individual, and it is pre-
sent for more than three months. Chronic kidney 
disease is a general term for heterogeneous disor-
ders affecting kidney structure and function with 
variable clinical presentation (1). Rational approach 
to the diagnosis and evaluation of CKD involves si-
multaneous assessment and monitoring of renal 
function (through estimated glomerular filtration 
rate (eGFR), serum creatinine) and kidney damage 
(albuminuria and/or proteinuria) (Table 1).
One of the prominent criteria for the diagnosis of 
CKD is decreased GFR value (< 60 mL/min/1.73m2). 
GFR is widely accepted as the best index of kidney 
function. The normal value in young adult men 
and woman is approximately 125 mL/min/1.73m2. 
Values below 15 mL/min/1.73m2 indicate kidney 
failure and the person can be identified as a candi-
date for dialysis or renal replacement therapy/kid-
ney transplantation (1). The role of laboratory 
medicine in diagnosis and management of CKD is 
of great importance because a very simple test 
can identify people who are at risk of developing 
CKD. All that is required is measuring the concen-
tration of serum creatinine and reporting of eGFR, 
using the available predictive equations.
For an initial assessment of proteinuria the follow-
ing measurements are recommended (in descend-
ing order of preference):
1. urine albumin-to-creatinine ratio (ACR), or





1. Albuminuria (AER ≥ 30 mg/24 hours; ACR 
≥ 3 mg/mmol)
2. Urine sediment abnormalities
3. Electrolyte and other abnormalities due 
to tubular disorders
4. Abnormalities detected by histology
5. Structural abnormalities detected by 
imaging
6. History of kidney transplantation
Decreased 
GFR
GFR < 60 mL/min/1.73 m2 (GFR categories 
G3a - G5)
*Either of the following should be present for > 3 months. 
AER - albumin excretion rate. ACR - albumin-to-creatinine 
ratio. GFR - glomerular filtration rate.
(Reproduced with permission from KDIGO 2012 Clinical 
Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
Table 1. Criteria for chronic kidney disease (CKD) diagnosis*
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In all cases an early morning urine sample is pre-
ferred, but does not exclude spot urine samples. 
Measuring the concentration of urine albumin is 
preferred to measuring the concentration of urine 
total protein. Use of urine albumin measurement 
as the preferred test for proteinuria detection will 
improve the sensitivity, quality, and consistency of 
the approach to early detection and management 
of kidney disease. Albumin (or total protein) con-
centration in the urine sample should be reported 
in proportion to the concentration of creatinine 
(ACR or PCR) in the same sample to minimize the 
influence of the patient’s hydration and the con-
centration of the urine sample. The reporting of 
the results is the same for both first morning and 
spot urine samples, respectively. A positive finding 
of albuminuria in a random sample of urine needs 
to be confirmed in the next morning void urine. If 
a more accurate assessment of albuminuria (or to-
tal proteinuria) is required, it is recommended to 
measure albumin excretion rate (AER) or total pro-
tein excretion rate in a timed urine sample (1,5,6). 
The choice of a suitable timed sample type should 
be of a laboratory manager. Adequate sample 
type, time of collection and instructions for pa-
tients should be provided by institution.
Some of the other laboratory criteria for diagnos-
ing CKD include urine sediment abnormalities as 
markers of kidney damage (Table 1). This may in-
clude some formed elements, such as renal tubu-
lar cells, red blood cells (RBC) casts, white blood 
cell (WBC) casts, coarse granular casts, wide casts 
and large numbers of dysmorphic RBCs. Abnor-
malities of electrolytes (Table 1) may result from 
disorders of renal tubular reabsorption and secre-
tion. These syndromes are uncommon but patho-
gnomonic of kidney disease (1).
Grading of CKD is based almost exclusively on two 
laboratory parameters: eGFR (GFR categories 1 to 
5 (G1 – G5)) and albuminuria (albuminuria catego-
ries 1 to 3 (A1 – A3)) (Table 2). It is also used for the 
prognosis of progression of the disease (1).
Depending on the category, patients are classified 
as low-risk patients, highlighted in green, moder-
ate risk (yellow), high risk (orange) and very high 
risk patients (highlighted in red). 
CKD testing using eGFR and ACR should be of-




•	 acute kidney injury 
•	 cardiovascular disease (ischaemic heart disease, 
chronic heart failure, peripheral vascular dis-
ease or cerebral vascular disease)





































G1 Normal or high ≥ 90
G2 Mildly decreased 60 – 89
G3a Mildly to moderately decreased 45 – 59
G3b Moderately to severely decreased 30 – 44
G4 Severely decreased 15 – 29
G5 Kidney failure < 15
Green represents low risk (if no other markers of kidney disease, no CKD). Yellow represents moderately increased risk. Orange 
represents high risk. Red represents very high risk. 
(Reproduced with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney 
Disease. Kidney Int, Suppl 2013;3:1-150.)
Table 2. Prognosis of CKD by eGFR categories and albuminuria: KDIGO 2012 
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•	 structural renal tract disease, recurrent renal 
calculi or prostatic hypertrophy
•	 multisystem diseases with potential kidney in-
volvement – for example, systemic lupus ery-
thematosus
•	 family history of end-stage kidney disease (GFR 
category G5) or hereditary kidney disease
•	 opportunistic detection of haematuria (7).
Background
Recently, it was shown that laboratory diagnostics 
of chronic kidney disease in Croatia is not stand-
ardized (8). There is a large heterogeneity among 
Croatian medical biochemistry laboratories re-
garding creatinine methods and used reference 
intervals and types of preferred samples for urine 
albumin (or protein). The most important issue 
that occured is the fact that laboratories still use 
non-standardized methods for creatinine results 
and do not report eGFR values. Also, the majority 
of laboratories do not measure urine albumin, es-
pecially in primary care health setting (8). These 
facts set the background for the process of stand-
ardization and harmonization in this area of labo-
ratory medicine. These national guidelines, based 
on the relevant 2012 KDIGO Guideline (1), repre-
sent the first step in accomplishing this goal.
Key factors for laboratories implementing the na-
tional guidelines for the diagnosis and manage-
ment of CKD are:
1. Ensure good communication between labora-
tory professionals and relevant clinicians, such 
as nephrologists or specialists in general/family 
medicine,
2. Ensure all patients are provided with the same 
availability of laboratory diagnostics,
3. Ensure creatinine assays are traceable to isotope 
dilution mass spectrometry (IDMS) method and 
have minimal bias and acceptable imprecision,
4. Select the appropriate GFR estimating formu-
la. Recommended equation is the 2009 Chron-
ic Kidney Disease Epidemiology Collaboration 
(CKD – EPI) equation,
5. In reporting the key laboratory tests (creatinine, 
eGFR, urine albumin-to-creatinine ratio (ACR), 
urine protein-to-creatinine ratio (PCR)) use the 
appropriate reporting units, 
6. Provide adequate information on limitations to 
creatinine measurement (9).
Recommedations
The national recommendations are mainly based 
on the KDIGO 2012 guidelines, however, novel lit-
erature findings are also incorporated. Our main 
goal was to provide recommendations that can be 
easily applied in every medical biochemistry labo-
ratory in Croatia. The draft of the recommenda-
tions was sent to numerous national and interna-
tional experts for their comments. The manuscript 
was also made available for public consultation. All 
comments were carefully considered and incorpo-
rated into the final version of the recommenda-
tions.






















The manuscript is organized to identify critical 
points in four major laboratory tests used in basic 
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laboratory diagnostics of CKD. It is rather difficult 
to give unique and uniform recommendations, re-
garding a large heterogeneity amongst methods 
and populations. Our intention was to point out to 
some weak points in pre- and analytical phase, but 
every laboratory must set their own specifications 
for method performance and handling the speci-
mens, according to their possibilities and condi-
tions.
An easy-to-follow step-by-step approach in imple-
mentation of the recommendations is shown in 
Appendix 1.
To ensure the better flow of information in imple-
menting national guidelines laboratories can use 
the provided template (Appendix 2) (10).
1 . Creatinine
An important limiting factor in the use of predic-
tive equations for GFR estimation is an accurate 
method for determining serum creatinine concen-
tration. 
1 .1 . Preanalytical phase 
There are numerous well known preanalytical vari-
ations that affect serum creatinine concentration 
which are listed in the Table 3. 
The majority of listed variations are non-controlla-
ble, however both laboratory professionals and cli-
nicians should be aware of those limitations. The 
laboratory professionals are referred to previously 
Source of error Example Actions
Non-controllable variations
Non-steady state AKI
Laboratory professionals and clinicians should be 
aware of listed limitations.





Extremes in muscle mass (body building, anorexia)
Diet/nutrition (high protein diet, creatine 
supplements, creatine, vegetarians)
Muscle wasting diseases (muscular dystrophy, 
rhabdomyolysis)
Ingestion of cooked meat
Factors affecting 
tubular secretion of 
creatinine






Decrease by gut creatininase by antibiotics
Increased by large volume losses of extracellular fluid




Spectral interference (eg. bilirubin, some drugs)
Chemical interference (eg. glucose, ketones, 
bilirubin, some drugs)
Lipemia (serum delipidation with heparin and 
MgCl2 may cause falsely decreased creatinine 
concentration)
For obtaining an adequate blood sample 
laboratory professionals should implement the 
valid national recommendations for venous and 
capillary blood sampling (References: 11, 12)
For management of lipemic samples please 
consult a review by Nikolac et al. (Reference: 25)
Regarding analytical interferences, laboratory 
professionals should verify the data declared 
by the manufacturer and define their own 
acceptability criteria.
AKI - acute kidney injury. GFR - glomerular filtration rate.
(Reproduced with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney 
Disease. Kidney Int, Suppl 2013;3:1-150.)
Table 3. Sources of errors in GFR estimation using creatinine 
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mentioned Appendix 2 which will be of assistance 
in communication with patients, as well as with 
the ordering physicians. For a minor part of varia-
tions that can be controlled regarding sample 
quality, laboratory professionals are referred to the 
published national recommendations for venous 
and capillary blood sampling (11,12). 
Stability
Creatinine, in a non-separated serum sample, 
which is in contact with a blood clot, is stable for 
24 hours. In a separate serum sample creatinine is 
stable for 7 days at room temperature (20-25 °C), 
or stored in a refrigerator (2-8 °C). Serum samples 
stored at - 20 °C are stable for 3 months with 10 
freeze-thaw cycles (13). 
1 .2 . Analytical phase
To universally implement eGFR based on serum 
creatinine measurements, standardization of rou-
tine serum creatinine measurements is required. 
For the measurement of serum creatinine, labora-
tories should use the recommended method with 
calibration traceable to international standard ref-
erence material and minimal bias compared to the 
IDMS method (1).
Desirable and optimal specification for impreci-
sion, bias and total error according to biological 
variation database (14,15) are shown in Table 4.
Recommended methods for serum creatinine 
measurements in Croatia are: photometric com-
pensated Jaffé method traceable to IDMS method 
and enzymatic method traceable to IDMS method 
and The National Institute of Standards and Tech-
nology Standard Reference Material (NIST SRM) 
967 for creatinine in serum (16). However, there is 
emerging evidence that enzymatic creatinine as-
says lead to less variability in measurements of se-
rum creatinine and are preferably used in clinical 
practice in order to generate more reliable GFR es-
timates (17-19).
Standardization (compensation) of photometric 
Jaffé method involves changing the values of cali-
brators in terms of traceability to the IDMS meth-
od and change of corresponding intercept (or fac-
tor B, depending on the analyzer). Considering the 
fact that there are many creatinine assays available 
that may not be IDMS traceable, and that for as-
says which may be IDMS traceable, the informa-
tion supplied does not make this clear to the user 
(20), for new values of calibrators, controls and in-
tercept, laboratory professionals should contact 
the person in charge of applications from compa-
nies providing reagents, controls and calibrators 
or whose analyzer is on which creatinine is meas-
ured. The list of available creatinine assays, as well 
as traceability information, is given in the Appen-
dix 3. However, laboratory professionals should be 
aware that this list is susceptible to changes and 
they should always be correctly informed by the 
latest Information for use (IFU) leaflet.
Standardization of calibration does not correct for 
analytical interferences. The enzymatic assays may 
be less influenced by non-creatinine chromogens 
Desirable specification Optimal specification
I (%) B (%) TE (%) I (%) B (%) TE (%)
Serum creatinine 3.0 4.0 8.9 2.8 3.2 7.7
Creatinine, concentration, first morning urine 11.6 8.7 27.8 NA NA NA
Total protein, 24 hour urine 17.8 10.7 40.0 8.9 5.3 20.0
Albumin, concentration, first morning urine 18.0 16.4 46.1 9.9 7.0 23.3
I – specification for imprecision. B – specification for inaccuracy. TE – specification for allowable total error. NA – not applicable.
Table 4. Specifications for imprecision, inaccuracy and allowable total error
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compared to the Jaffé assays (21,22), but no proce-
dure was unaffected. The most common analytical 
interferences are caused by endogenous sub-
stances: high bilirubin concentration, glucose, pro-
teins, pyruvate, β-hydroxybutyric acid, low albu-
min, as well as many drugs (cephalosporins, dobu-
tamine, lidocaine) (23). High bilirubin concentra-
tions may interfere with the Jaffé method, where 
the assay absorbance is near the bilirubin absorb-
ance peak of ~456 nm. Jaffé reaction may also be 
affected by lipemia and/or haemolysis. Haemo-
lysed samples that contain fetal haemoglobin 
(HbF) interfere with the Jaffé reaction, and it is 
possible to obtain negative creatinine results (24). 
Management of lipemic samples was extensively 
explained in the review by Nikolac et al. (25).
The influence of interfering substances is greater 
at creatinine concentrations within reference 
range than at higher concentrations. Magnitude 
and direction of bias in creatinine concentration 
depends on the details of implementation of the 
method principle (26). The influence of interfering 
substances is less frequent with the enzymatic 
procedures, however no procedure is unaffected 
and is method and analyzer dependent (21,27). In-
terference (endogenous or exogenous) if unrecog-
nized lead to false laboratory result and conse-
quently to incorrect diagnosis. To systematize cor-
rective actions, as a part of the total quality sys-
tem, when interference appears first step must be 
manufacturer s´ method specification in which are 
listed interference studies conducted by the man-
ufacturer (28). However, it was shown that there 
are serious discrepancies between manufacturer’s 
declarations and measured data (29). Each labora-
tory should verify the data declared by the manu-
facturer and define its own acceptability criteria 
(30).
Because urine contains relatively little or no pro-
tein, both enzymatic and Jaffé method are suita-
ble for urine creatinine measurement (1).
1 .3 . Postanalytical phase
When reporting serum and urine creatinine con-
centrations obtained by a standardized assay, lab-
oratories should use revised reference intervals 
published by Croatian chamber of medical bio-
chemists (CCMB) in 2010 (31,32) which are shown 
in Table 5. 
The applicability of the recommended “common” 
reference intervals in all Croatian laboratories 
measuring serum creatinine concentrations were 
confirmed in the study conducted by Flegar-
Meštrić et al. (33). This fulfils the prerequisite for 
implementation of international guidelines for 
early diagnosis and prediction of progression of 
chronic kidney disease using glomerular filtration 
rate CKD-EPI estimating equation (34,35).
1 .4 . Pediatric considerations
Children show lower reference ranges for total 
protein, thus the protein error in Jaffé method is 
considerably smaller, which, in consequence, with 
restandardized Jaffé-type assays, could lead to 
negative values in children with a decreased mus-
cle mass (36). Therefore, the only recommended 
method for the measurement of serum creatinine 
in pediatric patients (individuals younger than 18 
years) is enzymatic assay (37). 
The persisting problem of pediatric reference in-
tervals has been substantially reduced with the es-
tablishment of a new comprehensive database of 
pediatric reference intervals as a part of the Cana-
dian Laboratory Initiative in Pediatric Reference In-
tervals (CALIPER) study (38,39). It should assist lab-
oratorians and pediatricians in interpreting test re-
sults more accurately. There are already some 
transference studies with other analytical plat-
forms and local populations, as recommended by 
the CLSI (40,41). Laboratory professionals should 
also be aware of the International Federation for 
Clinical Chemistry and Laboratory Medicine (IFCC) 
Pediatric Reference Range Initiatives with many 
useful information on this delicate topic (42). 
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Prenatal  (umbilical cord) 46 – 86
newborn babies 0 – 14 days 27 – 81
male, female 2 months ≤ 1 year 14 – 34
male, female 1 y ≤ 3 y 15 – 31
male, female 3 y ≤ 5 y 23 – 37
male, female 5 y ≤ 7 y 25 – 42
male, female 7 y ≤ 9 y 30 – 48
male, female 9 y ≤ 11 y 28 – 57
male, female 11 y ≤ 13 y 37 – 63
male, female 13 y ≤ 15 y 40 – 72
male adults (18 – 74 y) 64 – 104
female adults (18 – 74 y) 49 – 90
Urine creatinine 
(24 hour urine sample) mmol/24 hour
male, female 3 – 8 y 1.0 – 6.0
male, female 9 – 12 y 1.5 – 12.5
male, female 13 – 17 y 2.6. – 16.5
male adults 7.7 – 21.3
female adults 5.9 – 14.1
Urine creatinine 
(first morning sample) mmol/L
male adults 3.5 – 22.9
female adults 2.5 – 19.2
y – years. (Reproduced and adapted with the permission of Croatian Chamber of Medical biochemists, document in Croatian. 
Available at: http://www.hkmb.hr/obavijesti/arhiva2010/arhiva_2010.html.)
Table 5. Revised recommended methods and reference intervals for serum and urine creatinine measurement
Recommendations
1. Methods for serum creatinine measurement should be traceable to IDMS method and NIST SRM 967.
2. For urine creatinine measurement both enzymatic and Jaffé method are suitable.
3. When reporting serum and urine creatinine values obtained by a standardized assay, laboratories 
should use revised reference intervals published by CCMB.
4. The recommended method for serum creatinine measurement in pediatric patients (< 18 years) is the 
enzymatic assay.
5. For pediatric reference intervals consult CALIPER database (http://www.sickkids.ca/Caliperproject/
intervals/index.html ) and other available literature data, such as IFCC Pediatric Reference Range Ini-
tiatives (http://www.ifcc.org/task-force-paediatric-laboratory-medicine-web-pages/paediatric-refer-
ence-range-initiatives/).
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2 . eGFR
2 .1 . Equations
The recommended equation for GFR estimation in 
adult population (≥ 18 years) is CKD-EPI equation 
(1,43,44). The equation includes four variables: se-
rum creatinine concentration, age, sex and race 
(Table 6) (34). Although all equations for GFR esti-
mation are essentially mathematical abstractions 
that relate patients to the populations from which 
the equations were derived (45), there is growing 
body of evidence that CKD-EPI equation is superi-
or in general population (5,46), as well as in diabet-
ic patients (47-49). 
In situations where GFR estimating equations are 
limited including extremes of body size and age, 
conditions after limb amputation, pregnancy, se-
vere malnutrition or obesity, muscle wasting dis-
eases, paraplegia and quadriplegia, vegetarian 
diet, rapidly changing kidney function, when de-
termining eligibility for kidney donation or adjust-
ing dosage of toxic drugs that are excreted by the 
kidneys and in research projects in which estimat-
ing glomerular filtration rate is a primary goal, GFR 
should be measured using standardized creatinine 
clearance measurement (1,50).
2 .2 . Preanalytical phase
eGFR may be falsely decreased after a meal of high 
meat content, as blood creatinine concentration 
increases after meal intake (51). 
Blood creatinine is predominantly derived from 
muscle, eg. a muscular young man may have in-
creased serum creatinine concentration and a 
falsely lowered eGFR. eGFR increases by 2.3 mL/
min/kg of lean mass in healthy men (52). 
Low eGFR finding should be confirmed with a re-
peated sample taken after avoidance of meat for 
at least 12 hours. Spurious causes of low eGFR, 
such as high muscle mass, should be considered. 
Additionally, a low eGFR should prompt a check 
for proteinuria assessment (51).
2 .3 . Postanalytical phase
Diagnosis, prognosis prediction and progression 
of CKD using eGFR is not based on comparing the 
values to population based reference intervals but 
on diagnostic values defined as categories in clas-
sification system shown in Table 2. Implementa-
tion of equations listed in Table 6, in laboratory in-
formation system is necessary for calculating eGFR 
using CKD-EPI equation. Recommended equa-
tions relate to white race. For calculating eGFR in 
black race, obtained result must be multiplied by 
1.159. When reporting eGFR results, they should be 
rounded to a nearest whole number using the rec-
ommended units mL/min/1.73 m2. eGFR values 
should be reported with requests for serum creati-
nine concentration in adults (5).
Glomerular filtration rate physiologically decreas-
es with ageing by approximately 1 mL/min/year of 
age (52,53). Although an eGFR values < 60 mL/
2009 CKD-EPI EQUATION (adults ≥ 18 years)
Gender Serum creatinine (µmol/L) Equation (for patients ≥ 18 years)
Female ≤62 eGFR =144 x (creat / 62)-0.329x (0.993)age
Female >62 eGFR =144 x (creat / 62)-1.209x (0.993) age
Male ≤80 eGFR =141 x (creat / 80)-0.411x (0.993) age
Male >80 eGFR =141 x (creat / 80)-1.209x (0.993) age
For black race use a multiplier of 1.159
SCHWARTZ EQUATION (children <18 years) 
GFR (mL/min/1.73 m2) = (36.2 × height) / creatinine
(height in cm, serum creatinine in µmol/L)
Table 6. Recommended equations for GFR estimation
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min/1.73 m2 are very common in older people (5), 
it is predictive for increased risk of adverse clinical 
outcomes and age related diagnostic values for 
eGFR are not recommended in adults.
Based on the biological and analytical variation of 
serum creatinine, the reference change value 
(RCV) for eGFR is about 14%.
1 .4 . Pediatric considerations
For estimation of GFR in pediatric population we 
recommend Schwartz equation with obligatory 
use of enzymatic assay for the measurement of se-
rum creatinine concentration (54,55). The equation 
is applicable for children from 1 to 18 years old.
Routine calculation of eGFR is not recommended 
in children and youth (5). Every eGFR result calcu-
lated by Schwartz equation above than 75 mL/
min/1.73 m2 should not be reported as a whole 
number but as „> 75 mL/min/1.73 m2“. 
In children younger than 2 years of age with CKD, 
the GFR categories as per the adult in Table 2 do 
not apply; these children should be categorized as 
having normal, moderately reduced, or severely 
reduced age-adjusted GFR. No currently agreed 
upon set of international normative values or cat-
egories exist for GFR in children under the age of 
1-2 years. However, the international pediatric 
nephrology community has embraced the adult 
CKD staging system as per the 2002 KDOQI guide-
lines in children over the age of 2 years (1).
Recommendations
1. Laboratories should implement the 2009 CKD-EPI equation for estimation of GFR.
2. eGFR results should be reported with serum creatinine results in adults.
3. eGFR results should be rounded to a nearest whole number using the recommended units mL/
min/1.73 m2.
4. Age related diagnostic values for eGFR are not recommended in adults.
5. Low eGFR values should be confirmed with a repeat sample taken after avoidance of meat at least 12 
hours. Additionally, spurious causes of low eGFR should be considered and should prompt a check 
for proteinuria.
6. RCV for eGFR is ~14%.
7. The recommended equation for children under 18 years is the Schwartz equation.
8. Routine calculation of eGFR is not recommended in children and youth.
9. Every eGFR result calculated by Schwartz equation above than 75 mL/min/1.73 m2 should be report-
ed as „> 75 mL/min/1.73 m2”.
10. The GFR categories (listed in the Table 2) do not apply in children under 2 years of age.
3 . ACR
3 .1 . Preanalytical phase
Albumin intra- and inter-individual biological vari-
ation are important factors for selecting appropri-
ate urine sample, for the interpretation of the con-
firmation results and for assessing clinically signifi-
cant difference in albumin concentration. ACR in 
the first morning urine has a significantly lower in-
tra-individual variation, compared to the albumin 
concentration in 24-hour urine. This represents an 
important fact considering the pitfalls in collect-
ing 24-hour urine samples (56). Table 7 presents 
the factors affecting urinary ACR (1,57). 
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The majority of the variations listed are non-con-
trollable, however both laboratory professionals 
and clinicians should be aware of those limitations. 
Controllable variations include obtaining an ade-
quate urine sample. The patient should be ade-
quately prepared and told why a urine specimen 
requires to be examined. Instructions on how it 
should be collected should be given, ideally both 
orally and in written form, following the national 
recommendations issued by CCMB about stand-
ards of good laboratory practice in obtaining ade-
quate urine samples (58). Biological (in vivo) fac-
tors, changing the true concentration of a meas-
ured component, cause problems in the interpre-
tation of laboratory results, although the measure-
ment process itself is correct. They are called influ-
ence factors and patients should be adequately 
explained about possible interferences (59). 
Stability
Albumin is stable in urine samples without pre-
servatives at least one week when stored at 2-8 °C. 
For an extended period it is recommended to 
freeze the sample at –80 °C, without centrifuga-
tion or filtration. After sample thawing, possible 
precipitates can be easily removed by dissolving 
the sample at 37 °C. Blurry urine samples should 
be centrifuged (60). 
3 .2 . Analytical phase
Recommended methods for the measurement of 
urine albumin are immunochemistry assays, spe-
cific and precise at low albumin concentrations, 
that produce quantitative results in clinically rele-
vant range. Albumin is mainly measured using tur-
bidimetric assays. Currently there is no reference 
measurement procedure or standardized refer-
ence material recommended by the Joint Commit-
tee on Traceability in Laboratory Medicine (JCTLM). 
At the moment the LC-IDMS method developed at 
the Mayo Clinic Renal Reference Laboratory is un-
der validation at the National Institute for Stand-
ards and technology (NIST) before being submit-
ted to the JCTLM for listing (61). Most methods are 
standardized against the Standard Reference Ma-
terial 470 (SRM 470) distributed by the Institute for 
Reference Materials and Measurements (IRMM) of 
the European Commission (1), however the NIST 
SRM 2925 containing pure albumin intended for 
calibration of LC-IDMS is now available. The com-
mutability assessment of the NIST SRM 3666 con-
taining albumin in frozen human urine intended 
for calibration of routine measurements proce-
dures is at the moment under investigation (61). 
Since the results are expressed in proportion to 
the concentration of creatinine, urine creatinine 
should be measured in the same urine sample. 
Desirable and optimal specifications for impreci-
sion, bias and total error according to biological 
variation database (14) are shown in Table 4.
Samples with very high albumin concentration 
may give falsely low or normal results due to the 
prozone effect. In this case it is necessary to repeat 
the analysis after dilution of the sample. 
The main causes of variation in urine albumin 
measurement are outside the analytical process, in 
preanalytical (as described in the previous sub-
heading) and postanalytical phases (different 
units, different cut-off values, different ways of re-
porting the results). Other causes of variation are 
different forms of albumin in urine, which are sig-
nificantly different from each other even between 
healthy individuals. Urine albumin is exposed to 
modifying factors such as wide range of pH and 
ionic strength, high concentrations of urea, glucose 
and ascorbate, and cleavage by peptidases (62).
3 .3 . Postanalytical phase
The presence of albumin in urine should be ex-
pressed as categories of classification system 
shown in Table 2. The term microalbuminuria is no 
longer recommended.
The results should be reported as ACR expressed 
as mg/mmol. If the presence of albumin in urine is 
measured as AER results should be reported using 
the units mg/24 hours with reference interval < 30 
mg/24hours, independently of sex and age.
3 .4 . Pediatric considerations
There is no set standard encompassing all children 
with respect to the normal range of urinary protein 
(or albumin) excretion. Values vary across age, sex, 
Biochemia Medica 2017;27(1):153–76  http://doi.org/10.11613/BM.2017.019 
164
Radišić Biljak V. et al. CSMBLM and CCMB recommendations for CKD testing 




Laboratory professionals and clinicians should be aware 
of listed limitations.
For a better flow of information please consult the 
Appendix 2.
Non-renal causes 
of variability in 
creatinine excretion
Age (lower in children and elderly)
Race (lower in Caucasians than black people)
Muscle mass (lower in people with amputations, 
paraplegia, muscular dystrophy)







Symptomatic urinary tract infections
Exercise
Orthostatic proteinuria
Other conditions increasing vascular permeability 
(eg. septicemia, significant hypertension, fever)
For obtaining an adequate sample laboratory 
professionals should implement standards of good 
laboratory practice issued by CCMB, available at: http://
www.hkmb.hr/povjerenstva/strucna-pitanja.html
Patients should be thoroughly explained about possible 
in vivo influence factors.Transient elevation 
in proteinuria
Vaginal and urethral secretions contamination
Exercise
Dehydration
Very high protein intake
Emotional stress





Degradation of albumin before analysis
Albumin is stable in urine samples without pre ser vatives at 
least one week when stored at 2-8 °C. 
For an extended period it is recommended to freeze the 
sample at - 80 °C, without centrifugation or filtration. 
After thawing of the sample, possible precipitates can 
be easily removed by dissolving the sample at 37 °C. 
Blurry urine samples should be centrifuged. 
Degradation of total protein before analysis
The proteins are susceptible to bacterial degradation 
at room temperature. Analysis should be performed as 
quickly as possible. Samples may be stored for up to 1 
week at + 4 °C, for longer storage frozen at -20 °C or  at 
- 80 °C. Samples should be dissolved at 37 °C to prevent 
degradation of proteins and after homogenizing, 
samples should be centrifuged prior to analysis 
ACR - albumin-to-creatinine ratio. PCR - protein-to-creatinine ratio. AKI - acute kidney injury. CCMB - Croatian Chamber of Medical 
Biochemists.
(Reproduced and adapted with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of 
Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.) 
Table 7. Factors affecting urinary ACR and PCR 
puberty, the presence of obesity (high BMI) and 
may be modified by exercise, fever and posture (1). 
In children with CKD any expression of abnormal 
urinary protein excretion may utilize proteinuria in 
place of albuminuria. Children older than 24 
months of age are expected to achieve normal 
(adult) protein values (1). 
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4 . PCR
4 .1 . Preanalytical phase
Filtered serum proteins, proteins derived from the 
kidney and urinary tract make normal urine pro-
tein content (63). Their appearance is influenced 
by renal, pre- and postrenal conditions (64). Urine 
as a body fluid for clinical analysis is relatively sta-
ble, probably due to the fact that it is “stored” for 
hours in the bladder; hence, proteolytic degrada-
tion by endogenous proteases may be essentially 
complete by the time of voiding (65).
Total protein in urine may be increased after heavy 
exercise, dehydration, very high protein intake and 
emotional stress (66). Vaginal and urethral secre-
tions can produce false positive, and diluted urine 
specimens can give false negative protein results 
(67). Because urine albumin is predominant pro-
tein in most proteinuric kidney diseases, all factors 
affecting urinary ACR also affect PCR (Table 7).
Stability
Proteins are susceptible to bacterial degradation 
at room temperature. Analysis should be per-
formed as quickly as possible. Samples may be 
stored for up to 1 week at + 4 °C, for longer stor-
age frozen at –20 °C or  at –80 °C. Samples should 
be dissolved at 37 °C to prevent degradation of 
proteins and after homogenizing, samples should 
be centrifuged prior to analysis (68). 
4 .2 . Analytical phase
There is no recommended method for measuring 
of total protein in the urine. The majority of labo-
ratories use turbidimetric or colorimetric assays. 
These methods do not have the same analytical 
specificity and sensitivity for all proteins. Most 
methods reacts more strongly with albumin than 
with globulins and other non-albumin proteins.
There is no reference method and no standardized 
reference material for urine protein recommended 
by JCTLM. Different methods and calibrators lead 
to significant between-laboratory variation. It is 
difficult to define a standardized reference materi-
al since a variable mixture of different proteins is 
measured (1).
Desirable and optimal specifications for impreci-
sion, bias and total error according to biological 
variation database (14) are shown in Table 4.
4 .3 . Postanalytical phase
Results of total urine protein measurement should 
be reported as PCR using the units mg/mmol (Ta-
ble 8).
Recommendations
1. Measure albumin preferably in a morning urine specimen.
2. Measure urine creatinine in the same urine sample.
3. Express the results as albumin-to-creatinine ratio (ACR) in recommended units (mg/mmol).
4. A positive finding of albuminuria in a random sample of urine needs to be confirmed in the next 
morning void urine.
5. If a more accurate estimate of albuminuria is required, it is recommended to measure albumin excre-
tion rate (AER), with reference interval < 30 mg/24hours, independently of sex and age.
6. In children with CKD proteinuria should be preferred over albuminuria, especially in children < 2 
years of age.
7. Adult values for AER and ACR apply for children older than 24 months of age.
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Category PCR
P1 
Normal to mild proteinuria < 15.0 mg/mmol
P2
Moderate proteinuria 15.0 - 50.0 mg/mmol
P3 
Severe proteinuria > 50.0 mg/mmol
Table 8. Protein-to-creatinine ratio’s categories in adults 
Unit <6 months 6 – 24 months > 24 months
PER mg/m2/day < 240 < 150 < 150
PCR mg/mmol / < 50 < 20
AER mg/day not known not known < 30
ACR mg/mmol not known not known < 3
PER – Protein Excretion Rate. PCR – Protein-to-Creatinine Ratio. AER – Albumin Excretion Rate. ACR – Albumin-to-Creatinine Ratio.
Table 9. Pediatric normal ranges for albuminuria and total proteinuria
Recommendations
1. Measure total protein preferably in a morning urine specimen.
2. Measure urine creatinine in the same urine sample.
3. Express the results as protein-to-creatinine ratio (PCR) in recommended units (mg/mmol).
4. A positive finding of proteinuria in a random sample of urine should be confirmed in the next morn-
ing void urine.
5. In adults, for a measure of protein excretion rate (PER) apply reference interval < 150 mg/24hours, 
independently of sex and age.
6. In children, the quantification of total protein, as compared to the albumin only fraction, may be pre-
ferred method.
Measurement of PCR to total protein concentra-
tion, in initial assessment of proteinuria, is to over-
come variation in urine concentration and dilution 
(63). 
4 .4 . Pediatric considerations
Neonates and young infants/children are both ex-
pected and allowed to have higher urinary losses 
of both glomerular and tubular proteinuria due to 
lack of maturation in the proximal tubular reab-
sorption of proteins. In children the quantification 
of total protein, as compared to the albumin only 
fraction, may be preferred method (1). 
The normal ranges for albuminuria and proteinu-
ria in children are shown in Table 9.
Conclusion
There are many issues that need to be resolved in 
the laboratory diagnostics of CKD in Croatia (8). Al-
though there were many potential biomarkers 
suggested for the early diagnosis of CKD (69, 70), 
considering the issues that were raised via the 
conducted survey (8), we need to approach the 
Croatian medical biochemistry laboratories at the 
very basic level.
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The principal clinical purpose of assessing a pa-
tient’s renal function is to anticipate complica-
tions, enabling better screening and treatment de-
cisions. Determining with great accuracy a certain 
physiologic parameter – actual GFR – is a less im-
portant goal (71) and inexpensive, easy and accu-
rate measurement of serum creatinine could lead 
to reduction in the global burden of CKD (3). In 
connection to this, the very first goal is to intro-
duce standardized assays for creatinine measure-
ment and eGFR reporting in all medical biochem-
istry laboratories. The second goal is to harmonize 
the choice of the sample for ACR/PCR measure-
ment and the reporting units, consequently. 
The future perspectives include education in im-
plementing the recommendations and conduct-
ing tho follow-up survey to observe the complete-
ness and identifying „weak spots“ of the recom-
mendations implementation process. The ob-
tained data will be a starting point for the second 
edition of the recommendations.
In conclusion, reporting the results of laboratory 
tests for the diagnosis of CKD should be aligned 
with the adopted general recommendations with 
the applicable reference intervals, diagnostic val-
ue, and the source is acknowledged criteria. An ex-
ample of the recommended reporting in labora-
tory diagnostics of CKD is shown in Table 10. 
Test/Analyte Results Unit Diagnostic value Reference
Estimation of glomerular filtration 





















P3:  > 50.0
KDIGO guidelines 
(2012.)
Table 10. Recommended reporting of laboratory results 
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appendix 1. Step-by-step flow chart for implementation of the recommendations for laboratory diagnostics of chronic kidney dis-
ease (CKD)
Creatinine eGFR ACR PCR
– serum creatinine
   measurement should
   be traceable to IDMS
   method and NIST SRM
   967
– the recommended
   method for the
   measurement of serum
   creatinine in pediatric
   patients (< 18 years)
   is enzymatic assay
– laboratories should
   implement the 2009
   CKD-EPI equation
   for estimation of GFR
– CKD-EPI eGFR results
   should be reported with
   serum creatinine results
   in adults
– the recommended
   equation for children
   from 1 to 18 years of
   age is Schwartz equation
– routine calculation of
   eGFR is not
   recommended in
   children and youth
– measure albumin
   preferably in a morning
   urine specimen
– measure urine creatinine
   in the same urine sample
– express the results as
   albumin-to-creatinine ratio
   (ACR) in recommended units
   (mg/mmol)
– adult values for AER and
   ACR apply for children
   older than 24 months of age
– measure total protein
   preferably in a morning
   urine specimen
– measure urine creatinine
   in the same urine sapmle
– express the results as
   protein-to-creatinine ratio
   (PCR) in recommended units
   (mg/mmol)
– in children the
   quantication of total
   protein, as compared to
   the albumin only fraction,
   may be preferred method
Laboratory diagnostics of CKD
appendix 2. Informations for physicians 
INFORMATIONS FOR PHYSICIANS:
Standardized creatinine and evaluation of estimated glomerular filtration rate
Question Answer
What is a standardized 
creatinine?
Standardized creatinine is a result of the determination of serum creatinine by method 
(enzymatic or compensated Jaffé) calibrated with standard NIST SRM 967th
Why we introduce a standardized 
creatinine?
Generally:
By standardization of creatinine we compensated systematic analytical error in current 
non-specific methods, which allowed standardization and enabled global comparability of 
results of serum creatinine and application of uniform reference intervals.
Specifically:
Standardized creatinine is a prerequisite for the implementation of international guidelines 
for the early diagnosis and monitoring progression of chronic kidney disease in risk 
populations (hypertension, diabetes, etc.).
Biochemia Medica 2017;27(1):153–76  http://doi.org/10.11613/BM.2017.019 
172
Radišić Biljak V. et al. CSMBLM and CCMB recommendations for CKD testing 
What is the relation of 
standardized creatinine results 
and creatinine?
Used methods showed a positive bias due to analytical interferention of exogenous and 
endogenous substances (pseudochromogene, most of the protein molecule, glucose, 
ketoacids), which provides a significant contribution to the intra- and inter-laboratory 
variability of results. To compensate part of non-specific interfering substances, the results of 
standardized creatinine are generally lower than that of creatinine.
Important! 
There is no conversion formula or factor linking standardized creatinine and creatinine .
What are the reference 
intervals for standardized 
serum creatinine for adults and 
how they are different from 
the reference intervals for 
creatinine?
Gender (age, years) Standardized creatinine Creatinine Units
Male
(18 – 74) 64 – 104 79 – 125 µmol/L
Female
(18 – 74) 49 – 90 63 – 107 µmol/L
What does this change in the 
longitudinal monitoring of renal 
function of the patient?
Absolute results of standardized creatinine and creatinine are not comparable; relative 
comparability is achieved by applying appropriate reference intervals!
What is eGFR?
eGFR is estimated glomerular filtration rate; calculated from serum creatinine and 
demographic characteristics of the patient (age, gender, race). 
For eGFR is not necessary to collect 24-hour urine!
Why we introduce eGFR?
eGFR is a prerequisite for the implementation of international guidelines for the early 
diagnosis and monitoring progression of chronic kidney disease in risk populations 
(hypertension, diabetes, etc.)
What is the recommended 
equation for calculating eGFR?
CKD-EPI equation with four variables (age, sex, race, concentration standardized serum 
creatinine) for adulthood.
Schwartz equation with two variables (height of the child, the concentration of a 
standardized serum creatinine) for children.
What are the units for eGFR? mL/min/1.73 m2
What are the reference intervals 
for eGFR?
There are none! We use eGFR for classification of renal impairment: 
Stage of chronic kidney disease Glomerular filtration (mL/min/1 .73 m2)
1 >= 90
2 60 – 89
3a 45 – 59
3b 30 – 44
4 15 – 29
5 <15
What are limitations of equations 
for estimating GFR? Schwartz equation requires the measurement of serum creatinine by enzymatic method.
When and whom can estimate 
GFR?
All persons in whom there is no acute condition, and determined the expression level of a 
standardized serum creatinine.
When and to whom can not be 
estimate GFR?
In states that follow acute changes of renal function, conditions after limb amputation and 
all states followed extreme changes in muscle mass. 
Very obese and malnourished people, pregnant women.
What is the role of creatinine 
clearance in the assessment of 
renal function?
Creatinine clearance is used for the measurement of the glomerular filtration rate. 
However, there are numerous sources of variability that compromise the accuracy of 
the results (physiological - tubular secretion of creatinine, pharmacologically - diuretics, 
analytical - interfering, practical - errors in collecting 24-hour urine). 
Therefore, to estimate glomerular filtration rate is recommended eGFR calculation from 
serum creatinine
(Adapted from an internal document of the Merkur University Hospital, reproduced with the written permission from the authors: 
Vučić Lovrenčić M, Flegar-Meštrić Z, Sabljar-Matovinović M.)
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appendix 3. Currently available creatinine reagents with the information on assay traceability – unpublished data from Radišić Biljak 
V and Jones G.
Company Test Kit Name Assay Type Supplied Calibration Information “IDMS traceable”
Abbott - Jaffe Calibrator values traceable to SRM 967 using IDMS Yes
Abbott - Enzymatic Calibrator values traceable to SRM 967 using IDMS Yes
Abbott Creatinine Jaffe For information on calibrator standardization, refer to Multiconstituent Calibrator package insert. Not declared
Abbott Creatinine (Enzymatic) Enzymatic
For information on calibrator standardization, refer 
to the MULTIGENT Clin Chem Cal package insert Not declared
Abbott i-STAT creatinine Enzymatic (whole blood)
Creatinine values assigned to i-STAT controls and 
calibration verification materials are traceable to the 
US National Institute of Standards and Technology 
(NIST) standard reference material (SRM967). Further 
information available from Abbott.
Yes
Accurex AutoZyme Creatinine Jaffe Not specified Not specified
AMS 
Diagnostics Creatinine Reagent Jaffe
Use an aqueous creatinine standard or an 
appropriate serum calibrator Not specified
Arkray Spotchem creatinine Reagent strip Spot chem calibrator or calibration by reagent card Not specified
Audit 
Diagnostics Creatinine Jaffe Jaffe Standard (177 μmol/L) Not specified
Beckman 
Coulter CR-S Jaffe IDMS (in calibrator IFU, Aqua Cal) Yes
Beckman 
Coulter CR-E Enzymatic IDMS (in calibrator IFU, Aqua Cal) Yes
Beckman Coulter 
(Olympus) Creatinine Jaffe
Cal values Traceable NIST or Thermo Fisher Scientific 
2 / NERL or reference methods. Yes
Beckman 
Coulter Creatinine Jaffe
Cal values traceable to NIST SRM 967 for method A.  








endpoint Creatinine standard supplied (2.0 mg/dL) Not specified
BioMed 
Diagnostics Creatinine Jaffe, fixed rate Creatinine standard supplied (2.0 mg/dL) Not specified
Biotecnica Creatinine Jaffe
The concentration of the supplied standard was 
determined using the NIST 914a international 
standard.
Yes
BQ Kits Creatinine Liquid Reagents Assay Enzymatic Calibrator included. Traceable to NIST SRM 914a. Yes
Chemhouse Creatinine (kinetic, Jaffes method) Jaffe Creatinine standard 2 mg/dL Not specified
Diasys Creatinine FS Jaffe Standard (2 mg/dL). Subtract 27 μmol/L for compensated method Yes
Diasys Creatinine PAP FS Enzymatic Standard (2 mg/dL). Yes
Diazyme Enzymatic creatinine Enzymatic
calibrator provided is traceable to NIST’s SRM 967 
(GC-IDMS and LC-IDMS) Yes
Biochemia Medica 2017;27(1):153–76  http://doi.org/10.11613/BM.2017.019 
174
Radišić Biljak V. et al. CSMBLM and CCMB recommendations for CKD testing 
Fortress 
diagnostics Creatinine Jaffe
For automated systems recommend a serum based 
calibrator to eliminate any matrix bias which may 











For automated use we recommend a serum based 
calibrator to eliminate any matrix bias which may 
be observed with the aqueous standard. Fortress 
Calibrator cat. No BXC0321K/L/M
Yes
Fujifilm Dri-chem slide CRE-PIII
Enzymatic (for Fuji 
analyser)
Traceability of Calibrators: NIST (SRM 914) Note 
reference material is applied to the reference 
method of Fujifilm corporation and is not directly 
applicable to the Fuji dri-chem slide
Yes
Genzyme Creatinine-S Assay Jaffe Calibration material not supplied Not specified
I .S .E . S .r .l . Creatinine Jaffe Multicalibrator I.S.E code R030000006 Not specified
IBL America Creatinine Liquid Reagents Assay Enzymatic Calibrator included. Traceable to NIST SRM 914a. Yes
ID Labs IDTox Creatinine Enzymatic Jaffe, microplate Standard “20 g/dL” Not specified
Ortho Clinical 




blood - Not specified Adjustable
Piccolo Kidney Check Enzymatic Not specified Not specified
Pointe Scientific Creatinine reagent set Jaffe
Use an NIST traceable creatinine standard (2.5 mg/
dL) or serum calibrator. Not specified
Pointe Scientific Creatinine reagent set Enzymatic
Use an NIST traceable creatinine standard (2.5 mg/
dL) or serum calibrator. Not specified
Robonik Prietest Creatinine Jaffe Standard provided (2 mg/dL) Not specified
Roche Creatinine Jaffe method Jaffe
This method has been standardised against IDMS 
(Isotope Dilution Mass Spectrometry). For the 
USA the method has been standardised against a 
primary reference mterial (SRM 914).
Yes
Roche Creatinine Jaffe Gen.2 Jaffe
This method has been standardised against IDMS 
(Isotope Dilution Mass Spectrometry). For the USA 
the method has been standardised against a primary 
reference material (SRM 914 and SRM 967 (IDMS)).
Yes
Roche Crea plus Enzymatic This method has been standardised against IDMS (Isotope Dilution Mass Spectrometry). Yes










Jaffe Not specified Yes
Sentinel Creatinine Jaffe IFU not seen Not specified
Sentinel Multigent Creatinine Enzymatic correlation with Roche enzymatic (on DXc) Yes
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Siemens -Advia - Jaffe IFU not seen - Claim at NKDEP Yes
Siemens - Advia - Enzymatic IFU not seen - Claim at NKDEP Yes
Siemens - 





Creatinine - Jaffe 
(single reagent) Jaffe Standard 2 mg/dL Not specified
Spinreact Creatinine Jaffe
Calibration with aqueous calibrator may cause a 
systematic error in automated procedures. In these 
cases it is recommended to use a serum calibrator.
Not specified
Spinreact Creatinine Enzymatic
Calibration with aqueous calibrator may cause 
matrix related bias, it is recommended to use a 
serum based calibrator.
Not specified






“Calibrator or suitable aqueous creatinine standard”. 
“An aqueous standard or serum based calibrator 
with and assigned value traceable to a primary 
standard (eg. NIST or IRMM) is recommended”
Not specified
Thermo Creatinine reagent - Enzymatic Enzymatic
An aqueous standard or serum based calibrator with 
an assigned value traceable to a primary standard 
(eg. NIST or IRMM) is recommended
Not specified
VITROSCIENT Creatinine (fixed rate) Jaffe Standard not defined Not specified
VITROSCIENT Creatinine (fixed rate)
Jaffe, 
deproteinised Standard not defined Not specified
WAKO Creatinine M L-type Enzymatic Wako system calibrator (available separately) Not specified
Wiener Creatinina directa Jaffe Standard 20 mg/L creatinine solution Not specified
Wiener Creatinina directa Enzymatic Wiener Lab Calibrator (3 values for creatinine depending on Wiener method) Not specified
DiaSystem 
Scandinavia AB Creatinine Jaffe Jaffe
Calibrators traceable to NIST 9167, subtract 27 
μmol/L Yes
Medichem Enzymatic Not specified Not specified
Randox Enzymatic Not specified Not specified
Diachem CREATININE ENZYMATIC Enzymatic
Calibration: S2: Creatinine standard found in the kit 
or Roche C.F.A.S. (Calibrator for automated system) 
or Roche cfas or Randox cal Li or level II
Not specified




(Mod Jaffe’s kinetic 
method)
Jaffe Supplied standard 177 μmol/L. “standard is traceable to standard reference material (SRM) 909b.” Not specified




Creatinine-LR Jaffe Supplied standard 177 μmol/L. Not specified
KEE GAD Biogen Creatinine (Jaffe’s method) Jaffe Supplied standard 177 μmol/L. Not specified
Recombigen Creatinine (Alkaline Picrate method)
Jaffe with 
deproteinisation Supplied standard 177 μmol/L. Not specified
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Supplied standard 177 umol/L. “Organic matrix 
based primary standard. Concentration value is 






Enzymatic test strips 
for use in CadioChek 
PA analyser
predicate device comparison: A = 0.93 x B +0.49 mg/
dL Not specified
bioMerieux SA Créatinine cinétique (CREA) Jaffe
- Use Calimat (Ref. 62 321): multiparametric calibrator 
linked with SRM 909 
or 
 - Use Reagent 1 (Ref. 61 162) linked with SRM 914 
Titer of Reagent 1:132.6 μmol/L 
Aqueous solution prepared using 99% pure creatinine
Not specified
Dijagnostika 
d .o .o . Kreatinin kinetički Jaffe
An aqueous standard or serum based calibrator with 
and assigned value traceable to a primary standard 
(eg NIST or IRMM) is recommended
Not specified
Dijagnostika 
d .o .o .
Kreatinin DST 
(liquid) Jaffe
An aqueous standard or serum based calibrator with 
and assigned value traceable to a primary standard 
(eg NIST or IRMM) is recommended
Not specified





Enzymatic ABX Pentra Multical required Not specified
Human auto-CREATININE liquicolor Jaffe
auto-CREATININE is calibrated with AUTOCAL, which is 
traceable to the reference material SRM 909b level 2. Not specified
Human CREATININE (ENZYM) liquicolor Enzymatic The method is traceable to the SRM 909c. Not specified
Human CREATININE liquicolor Jaffe The method is traceable to the SRM 909b Not specified
